Orbis BioCapital takes 9.98% stake in Universe Pharma

Universe Pharmaceuticals INC (UPC) received a Schedule 13G indicating that Orbis BioCapital Limited and Chunhua Zheng collectively report beneficial ownership of 499,926 Class A ordinary shares.

Rhea-AI Filing Summary

Universe Pharmaceuticals INC (UPC) received a Schedule 13G indicating that Orbis BioCapital Limited and Chunhua Zheng collectively report beneficial ownership of 499,926 Class A ordinary shares. This represents 9.98% of the Class A ordinary shares outstanding, based on 5,008,313 shares outstanding as of July 27, 2026.

Both Orbis BioCapital Limited, a British Virgin Islands company, and Chunhua Zheng, an individual resident in China, report shared voting and dispositive power over these 499,926 shares and no sole voting or dispositive power. Orbis BioCapital Limited is wholly owned and controlled by Chunhua Zheng.

Key Figures

Shares beneficially owned: 499,926 Class A ordinary shares Percent of class: 9.98% Shares outstanding: 5,008,313 Class A ordinary shares +2 more

5 metrics

Shares beneficially owned 499,926 Class A ordinary shares Beneficial ownership reported by Orbis BioCapital Limited and Chunhua Zheng

Percent of class 9.98% Ownership percentage of UPC Class A ordinary shares for each reporting person

Shares outstanding 5,008,313 Class A ordinary shares Shares outstanding as of July 27, 2026, used to calculate ownership percentage

Shared voting power 499,926 shares Number of shares over which each reporting person has shared voting power

Sole voting power 0 shares Number of shares over which each reporting person has sole voting power

Key Terms

beneficially owned, shared voting power, shared dispositive power, Schedule 13G, +1 more

5 terms

beneficially owned financial

"Item 4. | Ownership (a) | Amount beneficially owned: Orbis BioCapital Limited: 499,926.00"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

shared voting power financial

"6 | Shared Voting Power 499,926.00 7 | Sole Dispositive Power 0.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

shared dispositive power financial

"8 | Shared Dispositive Power 499,926.00 9 499,926.00"

Schedule 13G regulatory

""form_type": "SCHEDULE 13G""

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

percent of class financial

"(b) | Percent of class: Orbis BioCapital Limited: 9.98% Chunhua Zheng: 9.98%"

Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is the new significant shareholder of UPC disclosed in this Schedule 13G?

The Schedule 13G reports that Orbis BioCapital Limited and Chunhua Zheng together beneficially own 499,926 Class A ordinary shares of UPC, with shared voting and dispositive power over all of these shares.

What percentage of Universe Pharmaceuticals INC (UPC) does Orbis BioCapital Limited own?

Orbis BioCapital Limited reports beneficial ownership of 9.98% of UPC’s Class A ordinary shares, corresponding to 499,926 shares, based on 5,008,313 Class A ordinary shares outstanding as of July 27, 2026.

How many UPC shares are reported as beneficially owned by Chunhua Zheng?

Chunhua Zheng reports beneficial ownership of 499,926 Class A ordinary shares of UPC, the same shares held by Orbis BioCapital Limited, reflecting 9.98% of the Class A ordinary shares outstanding.

Does Orbis BioCapital Limited have sole or shared voting power over UPC shares?

Orbis BioCapital Limited reports 0 shares with sole voting power and 499,926 shares with shared voting power. It also reports 0 shares with sole dispositive power and 499,926 shares with shared dispositive power.

On what share count is the 9.98% ownership of UPC based?

The reported 9.98% ownership is calculated using 5,008,313 Class A ordinary shares of UPC outstanding as of July 27, 2026, as stated in the Schedule 13G.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/01/2026 - 06:08 PM EDT Accepted by SEC EDGAR 09/01/2026 - 06:07 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Universe Pharmaceuticals INC

(Name of Issuer)

Class A ordinary shares

(Title of Class of Securities)

G9442G138

(CUSIP Number)

07/27/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): G9442G138

1

Names of Reporting Persons

Orbis BioCapital Limited

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

VIRGIN ISLANDS, BRITISH

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 499,926.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 499,926.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

499,926.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.98 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: The amount in rows 6, 8 and 9 represents 499,926 Class A ordinary shares held by Orbis BioCapital Limited, a company with limited liability formed in the British Virgin Islands. Orbis BioCapital Limited is wholly owned and controlled by Chunhua Zheng, an individual. Percentage of class is calculated based on 5,008,313 Class A ordinary shares outstanding as of July 27, 2026.

SCHEDULE 13G

CUSIP Number(s): G9442G138

1

Names of Reporting Persons

Chunhua Zheng

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CHINA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 499,926.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 499,926.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

499,926.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.98 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: The amount in rows 6, 8 and 9 represents 499,926 Class A ordinary shares held by Orbis BioCapital Limited, a company with limited liability formed in the British Virgin Islands. Orbis BioCapital Limited is wholly owned and controlled by Chunhua Zheng, an individual. Percentage of class is calculated based on 5,008,313 Class A ordinary shares outstanding as of July 27, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Universe Pharmaceuticals INC
(b)	Address of issuer's principal executive offices: 265 Jingjiu Avenue, Jinggangshan Economic and Technological, Ji'an, Jiangxi, CHINA, 343100
Item 2.
(a)	Name of person filing: Orbis BioCapital Limited Chunhua Zheng
(b)	Address or principal business office or, if none, residence: Orbis BioCapital Limited: Vistra Corporate Services Centre, Wickhams Cay II, Road Town, Tortola, British Virgin Islands Chunhua Zheng: Room 802, Unit 6, Huayuwan Zone A17, Kunming Sunac Cultural City, Xishan District, Kunming, Yunnan Province 650100, People's Republic of China
(c)	Citizenship: Orbis BioCapital Limited: British Virgin Islands Chunhua Zheng: People's Republic of China
(d)	Title of class of securities: Class A ordinary shares
(e)	CUSIP Number(s): G9442G138
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Orbis BioCapital Limited: 499,926.00 Chunhua Zheng: 499,926.00
(b)	Percent of class: Orbis BioCapital Limited: 9.98% Chunhua Zheng: 9.98%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Row 5 of the cover page for each Reporting Person.
	(ii) Shared power to vote or to direct the vote: See Row 6 of the cover page for each Reporting Person.
	(iii) Sole power to dispose or to direct the disposition of: See Row 7 of the cover page for each Reporting Person.
	(iv) Shared power to dispose or to direct the disposition of: See Row 8 of the cover page for each Reporting Person.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Orbis BioCapital Limited

Signature:	/s/ Chunhua Zheng
Name/Title:	Chunhua Zheng/Director
Date:	09/01/2026

Chunhua Zheng

Signature:	/s/ Chunhua Zheng
Name/Title:	Chunhua Zheng
Date:	09/01/2026

Exhibit Information

Exhibit 99.1 - Joint Filing Agreement